ObsEva SA (OBSV)

1.830
+0.070(+3.98%)
After Hours
1.820
-0.010(-0.546%)
- Real-time Data
  • Volume:
    496,814
  • Bid/Ask:
    1.810/1.830
  • Day's Range:
    1.770 - 1.860

OBSV Overview

Prev. Close
1.76
Day's Range
1.77-1.86
Revenue
20.12M
Open
1.79
52 wk Range
1.75-5.54
EPS
-0.87
Volume
496,814
Market Cap
136.2M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
871,365
P/E Ratio
-
Beta
0.66
1-Year Change
-58.41%
Shares Outstanding
74,427,933
Next Earnings Date
Mar 10, 2022
What is your sentiment on ObsEva SA?
or
Market is currently closed. Voting is open during market hours.

ObsEva SA Company Profile

Employees
43

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellSellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • garbage
    0
    • ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
      0
      • I'm hoping for a $ 28 buyout in the next 8-10 months
        0
        • Total trash
          1
          • Stay away from this SCAM
            2
            • bought at $4,15bought at $3,80bought at $3,20I bought today at $2,85. when there is an positive update or developments in pipeline this can go straight up #HoldTheLine
              0
              • always down. SCAM
                2
                • this is a joke ....
                  1
                  • patience
                    0
                  • i'm not happy either
                    0
                • Irgendwann fliegt der Deckel und dann gehts richtig los !
                  3
                  • Ja ja
                    1
                • DON'T SELL! https://money.cnn.com/quote/forecast/forecast.html?symb=obsv#:~:text=Stock Price Forecast,the last price of 3.30.
                  1
                  • The worst stock i have ever bought...
                    1
                    • Verkaufe deine Aktien und morgen werden sie steigen... :  )
                      1
                  • I bought a few more shares today. maybe that was the last chance.
                    1
                    • this is a good moment to collect more shares and waiting for the Yselty® for uterine fibroids: NDA submission (Q2:21); MAA approval (Q4:21) 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀
                      0
                      • Bin auch dein Meinung
                        0
                      • Auch ich bin deiner Meinung..
                        0
                    • Hello all, I have been looking at OBSV from a distance and would like to know what make it a good buy, if at all?  It is rated as moderate buy and to me this is not so compelling. I appreciate your reply. Thanks.
                      0
                      • PowerPoint Presentation (obseva.com)
                        0
                      • Stefan Dörig thank you.  What is so special about this coming Friday and OBSV?
                        0
                    • look at the technical.. All manipulation
                      0
                      • 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀.... lets go baby...Friday is Obseva-Day!
                        0
                        • $16 target. Let's gooooo! 🚀🚀🚀
                          0
                          • do I here $7???
                            0
                            • Friday is Obseva-Day!
                              0
                              • Love this stock
                                0
                                • I just like the stock
                                  0
                                • Love is in the air
                                  0
                              • Force is strong in this one, long term play.
                                0
                                • Lame horse....😂
                                  0
                                  • Nit seeing moving up any time soon
                                    0
                                    • loooooong term play, this one will be a big provider for many maternity drugs for many hospitals and those are sticky customers.... if all goes well and gets FDA approved. I have locked in my trade and will not sell under $15
                                      0
                                      • Agree.
                                        0
                                    • will this ever move up ?
                                      0
                                      • Of course it will gain, no worries
                                        0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.